Polymer Nanocoating of Amorphous Drugs for Improving Stability, Dissolution, Powder Flow, and Tabletability: The Case of Chitosan-Coated Indomethacin

Overview

Journal Mol Pharm

Publisher American Chemical Society

Specialty Pharmacology

Date 2019 Jan 23

PMID 30668120

Citations 8

Authors

Yuhui Li

Junguang Yu

Shenye Hu

Zhenxuan Chen

Mark Sacchetti

Changquan Calvin Sun

Lian Yu

Affiliations

Soon will be listed here.

Abstract

As a result of its higher molecular mobility, the surface of an amorphous drug can grow crystals much more rapidly than the bulk, causing poor stability and slow dissolution of drug products. We show that a nanocoating of chitosan (a pharmaceutically acceptable polymer) can be deposited on the surface of amorphous indomethacin by electrostatic deposition, leading to significant improvement of physical stability, wetting by aqueous media, dissolution rate, powder flow, and tabletability. The coating condition was chosen so that the positively charged polymer deposits on the negatively charged drug. Chitosan coating is superior to gelatin coating with respect to stability against crystallization and agglomeration of coated particles.

Citing Articles

The Implications of Drug-Polymer Interactions on the Physical Stability of Amorphous Solid Dispersions.

Bookwala M, Wildfong P Pharm Res. 2023; 40(12):2963-2981.

PMID: 37389801 DOI: 10.1007/s11095-023-03547-4.

Enteric coating of tablets containing an amorphous solid dispersion of an enteric polymer and a weakly basic drug: A strategy to enhance in vitro release.

Nguyen H, Van Duong T, Taylor L Int J Pharm. 2023; 642:123139.

PMID: 37311499 PMC: 10390825. DOI: 10.1016/j.ijpharm.2023.123139.

A concise summary of powder processing methodologies for flow enhancement.

Shah D, Moravkar K, Jha D, Lonkar V, Amin P, Chalikwar S Heliyon. 2023; 9(6):e16498.

PMID: 37292344 PMC: 10245010. DOI: 10.1016/j.heliyon.2023.e16498.

Amorphous Drug-Polymer Salts.

Yao X, Neusaenger A, Yu L Pharmaceutics. 2021; 13(8).

PMID: 34452231 PMC: 8401805. DOI: 10.3390/pharmaceutics13081271.

Amorphous Drug-Polymer Salt with High Stability under Tropical Conditions and Fast Dissolution: The Case of Clofazimine and Poly(acrylic acid).

Gui Y, McCann E, Yao X, Li Y, Jones K, Yu L Mol Pharm. 2021; 18(3):1364-1372.

PMID: 33522821 PMC: 7927142. DOI: 10.1021/acs.molpharmaceut.0c01180.

References

Andronis V, Yoshioka M, Zografi G . Effects of sorbed water on the crystallization of indomethacin from the amorphous state. J Pharm Sci. 1997; 86(3):346-51. DOI: 10.1021/js9602711. View

Genina N, Raikkonen H, Ehlers H, Heinamaki J, Veski P, Yliruusi J . Thin-coating as an alternative approach to improve flow properties of ibuprofen powder. Int J Pharm. 2009; 387(1-2):65-70. DOI: 10.1016/j.ijpharm.2009.12.005. View

Shi L, Sun C . Transforming powder mechanical properties by core/shell structure: compressible sand. J Pharm Sci. 2010; 99(11):4458-62. DOI: 10.1002/jps.22172. View

Osei-Yeboah F, Sun C . Tabletability Modulation Through Surface Engineering. J Pharm Sci. 2015; 104(8):2645-8. DOI: 10.1002/jps.24532. View

Huang C, Ruan S, Cai T, Yu L . Fast Surface Diffusion and Crystallization of Amorphous Griseofulvin. J Phys Chem B. 2017; 121(40):9463-9468. DOI: 10.1021/acs.jpcb.7b07319. View

Zhu L, Brian C, Swallen S, Straus P, Ediger M, Yu L . Surface self-diffusion of an organic glass. Phys Rev Lett. 2011; 106(25):256103. DOI: 10.1103/PhysRevLett.106.256103. View

Yu L . Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001; 48(1):27-42. DOI: 10.1016/s0169-409x(01)00098-9. View

Fell J, Newton J . Determination of tablet strength by the diametral-compression test. J Pharm Sci. 1970; 59(5):688-91. DOI: 10.1002/jps.2600590523. View

Yu L . Surface mobility of molecular glasses and its importance in physical stability. Adv Drug Deliv Rev. 2016; 100:3-9. DOI: 10.1016/j.addr.2016.01.005. View

10.

Wu T, Sun Y, Li N, de Villiers M, Yu L . Inhibiting surface crystallization of amorphous indomethacin by nanocoating. Langmuir. 2007; 23(9):5148-53. DOI: 10.1021/la070050i. View

11.

Teerakapibal R, Gui Y, Yu L . Gelatin Nano-coating for Inhibiting Surface Crystallization of Amorphous Drugs. Pharm Res. 2018; 35(1):23. DOI: 10.1007/s11095-017-2315-z. View

12.

Murdande S, Pikal M, Shanker R, Bogner R . Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J Pharm Sci. 2009; 99(3):1254-64. DOI: 10.1002/jps.21903. View

13.

Andronis V, Zografi G . The molecular mobility of supercooled amorphous indomethacin as a function of temperature and relative humidity. Pharm Res. 1998; 15(6):835-42. DOI: 10.1023/a:1011960112116. View

14.

Alves N, Picart C, Mano J . Self assembling and crosslinking of polyelectrolyte multilayer films of chitosan and alginate studied by QCM and IR spectroscopy. Macromol Biosci. 2009; 9(8):776-85. DOI: 10.1002/mabi.200800336. View

15.

Hancock B, Parks M . What is the true solubility advantage for amorphous pharmaceuticals?. Pharm Res. 2000; 17(4):397-404. DOI: 10.1023/a:1007516718048. View

16.

Shi L, Sun C . Overcoming poor tabletability of pharmaceutical crystals by surface modification. Pharm Res. 2011; 28(12):3248-55. DOI: 10.1007/s11095-011-0518-2. View